Methods for treating cancer targeting transglutaminase

US8299040B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Kapil Mehta · Bellaire, US
• Amit Verma · Schweinhub, DE
• Sushovan Guha · Missouri City, US
• Jansina Fok · Houston, US
• Gabriel Lopez-Berestein · Bellaire, US
• Anil K. Sood · Kullu, IN

Key dates

• Filing date: Oct 5, 2007
• Grant date: Oct 30, 2012
• Expiry date: Nov 30, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).